Form 4: Amgen VP Matthew Busch Receives New Equity Awards

Amgen's VP of Finance and CAO Matthew C. Busch was granted 455 restricted stock units and 2,969 stock options as part of a long-term incentive plan.

Summary

• Matthew C. Busch, Vice President of Finance and Chief Accounting Officer, received 455 Restricted Stock Units (RSUs) on May 5, 2026.
• Busch also received 2,969 Non-qualified Stock Options (NQSOs) with an exercise price of $329.59 per share.
• On May 6, 2026, 50 shares were withheld by the company at a price of $329.59 to satisfy tax withholding obligations.
• Both the RSUs and the stock options are scheduled to vest in four equal annual installments of 25% each, starting May 5, 2027.
• Following these transactions, Busch directly owns 4,385 shares of common stock and holds 2,969 derivative securities.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as slightly positive; while routine, it confirms that key management personnel are being incentivized with equity at current market valuations, signaling internal confidence.

Positives

• Executive compensation is heavily weighted toward equity, aligning management's interests with those of long-term shareholders.
• The reporting person maintains a direct ownership stake of 4,385 shares, demonstrating skin in the game.
• The stock options have a 10-year term, expiring in 2036, which incentivizes long-term value creation.

Negatives

• The disposal of 50 shares, while for tax purposes, represents a minor reduction in the immediate direct holding.

Risks

• The stock options are granted at an exercise price of $329.59, meaning they will only provide value if the stock price appreciates above this level.
• Equity-based compensation is subject to market volatility and the company's ability to meet performance goals over a four-year vesting period.

Future Outlook

The four-year vesting schedule for these awards suggests a focus on executive retention and long-term strategic execution through at least 2030.

Management Comments

• The Restricted Stock Units and options vest in four equal annual installments of 25% each, commencing on 5/5/2027.
• Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

Industry Context

StockSavvy.ai notes that Amgen's use of a mix of RSUs and NQSOs is consistent with large-cap biotechnology peers who use these instruments to balance retention with performance-based incentives in a highly competitive talent market.

Comparison to Industry Standards

• The 4-year vesting period is a standard benchmark for S&P 500 companies, matching structures used by competitors like Gilead Sciences and Biogen.
• The use of a 10-year option term is the industry standard for non-qualified stock options in the pharmaceutical sector.

Related Party Transactions

• The reporting person received equity awards under the company's Second Amended and Restated 2009 Equity Incentive Plan.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign of executive alignment with stock price performance.
• The CAO's increased potential ownership stake reinforces management stability.

Next Steps

• The first 25% of the granted RSUs and options will vest on May 5, 2027.

Key Dates

Recommendation

This is a routine administrative filing regarding executive compensation. While it shows management alignment, it does not provide new material information regarding the company's clinical pipeline or financial performance that would alter a fundamental investment thesis.

Keywords

Amgen, AMGN, Insider Trading, Executive Compensation, Stock Options, Restricted Stock Units, Matthew Busch, Biotechnology